Doxol Drug Interactions

Docetaxel is metabolised by the cytochrome P450 isoenzyme CYP3A4 and use with inducers or inhibitors or other substrates of this enzyme may affect exposure to docetaxel. It should be given with caution to patients taking strong CYP3A4 inhibitors including.
HIV-protease inhibitors such as ritonavir, and azole antifungals like ketoconazole or itraconazole.
Concurrent use of rotavirus vaccine and chemotherapeutic agents may result in an increased risk of infection by the live vaccine. Hence it is contraindicated.
Concurrent use of docetaxel and thalidomide may result in an increased risk of venous thromboembolism.
Concurrent use of live vaccines and chemotherapeutic agents may result in an increased risk of infection by the live vaccine.
Concurrent use of docetaxel and doxorubicin may result in cholestatic jaundice and pseudomembranous colitis.
Concurrent use of docetaxel and itraconazole may result in an increased risk of docetaxel toxicity.
Concurrent use of docetaxel and the following may result in an increased risk of docetaxel toxicity (anemia, leukopenia, thrombocytopenia, fever, diarrhea): erythromycin, troleandomycin, indinavir, atazanavir, clarithromycin, ketoconazole, ritonavir, terfenadine, telithromycin, nefazodone, nelfinavir, cyclosporine, voriconazole.
Concurrent use of cisplatin and docetaxel may result in increased risk of neuropathy.
Concurrent use of docetaxel and sorafenib may result in increased docetaxel exposure and plasma concentrations.
Concurrent use of docetaxel and quinupristin/dalfopristin may result in an increased risk of docetaxel toxicity (neutropenia, anemia, neuropathy).
Concurrent use of docetaxel and doxorubicin hydrochloride liposome may result in increase in doxorubicin exposure.
Concurrent use of docetaxel and grapefruit juice may result in increased docetaxel exposure.